Published in Semin Immunol on August 17, 2011
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21
Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes (2005) 2.10
The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes (2008) 2.04
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes (2007) 1.98
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells. Diabetes (2005) 1.44
Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One (2010) 1.43
Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood (2009) 1.37
Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci U S A (2004) 1.32
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol (2002) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity (2006) 1.22
Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes (2006) 1.21
Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A (2003) 1.14
The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes. Cold Spring Harb Perspect Med (2012) 1.10
Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev (2006) 1.09
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol (2005) 1.08
Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology (2012) 1.08
G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J Immunol (2002) 1.06
Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci (2008) 0.98
ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. Diabetes (2012) 0.97
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol (2010) 0.96
Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med (2011) 0.96
Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood (2008) 0.95
Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway. J Immunol (2002) 0.95
A view on beta cell transplantation in diabetes. Ann N Y Acad Sci (2002) 0.94
Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol (2013) 0.92
Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target. PLoS One (2009) 0.90
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation (2005) 0.90
The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol (2004) 0.90
Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse. Int Rev Immunol (2005) 0.90
Toward cell-based therapy of type I diabetes. Trends Immunol (2008) 0.89
New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation? Curr Opin Organ Transplant (2010) 0.87
A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Semin Immunol (2011) 0.87
Weaned from the needle. Nat Med (2006) 0.86
Adaptive human regulatory T cells: myth or reality? J Clin Invest (2006) 0.85
FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis. Nephrol Dial Transplant (2009) 0.84
Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells. J Cell Mol Med (2012) 0.83
Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients. Diabetes Metab Res Rev (2002) 0.83
G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse. J Autoimmun (2005) 0.83
Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr Opin Gastroenterol (2004) 0.82
Genetic control of hepatitis A severity and susceptibility to allergy. J Clin Invest (2011) 0.82
Proinsulin: a unique autoantigen triggering autoimmune diabetes. J Clin Invest (2006) 0.81
Diabetes: type 1 diabetes mellitus--a door opening to a real therapy? Nat Rev Endocrinol (2011) 0.81
Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. J Allergy Clin Immunol (2013) 0.80
Concomitant early appearance of anti-ribonucleoprotein and anti-nucleosome antibodies in lupus prone mice. J Autoimmun (2003) 0.80
12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr (2008) 0.80
Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials. Rev Diabet Stud (2005) 0.80
Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord (2008) 0.80
Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: myth or reality? Curr Opin Organ Transplant (2011) 0.80
On the mechanisms of the protective effect of infections on type 1 diabetes. Clin Dev Immunol (2004) 0.79
Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol (2006) 0.79
CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. Adv Immunol (2008) 0.78
Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance. Expert Opin Biol Ther (2005) 0.78
Peripheral B-cell phenotype and BAFF levels are associated with HLA immunization in patients awaiting kidney transplantation. Transplantation (2014) 0.78
A Toll-like trigger for autoimmune disease. Nat Med (2005) 0.78
Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. PLoS One (2013) 0.77
In vivo activation of transferred regulatory T cells specific for third-party exogenous antigen controls GVH disease in mice. Eur J Immunol (2013) 0.76
Correction: Antibiotics in Early Life Alter the Gut Microbiome and Increase Disease Incidence in a Spontaneous Mouse Model of Autoimmune Insulin-Dependent Diabetes. PLoS One (2016) 0.75
[Not Available]. Bull Acad Natl Med (2014) 0.75
[French biological research: the excellence is there, and the next generation ready to take over]. Med Sci (Paris) (2009) 0.75
Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody. Blood (2006) 0.75
[From the XVIII Century (le Siècle des Lumières) and the Veterinary School creation until now: 250 years of fighting epizootics]. C R Biol (2012) 0.75
[Cardiovascular risk, cholesterol and statins]. Bull Acad Natl Med (2013) 0.75
Monitoring of anti-transglutaminase autoantibodies in pediatric celiac disease using a sensitive radiobinding assay. J Pediatr Gastroenterol Nutr (2012) 0.75
[The genetic determinism of polygenic diseases]. Bull Acad Natl Med (2005) 0.75